{
    "clinical_study": {
        "@rank": "68722", 
        "acronym": "MMV", 
        "arm_group": [
            {
                "arm_group_label": "Chloroquine and falciparum immunization", 
                "arm_group_type": "Active Comparator", 
                "description": "This arm will receive chloroquine prophylaxis, a placebo during immunizations and three times 5 infected mosquito-bites (immunizations). Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.\nPlacebo capsules daily on three consecutive days starting on each of three immunization days.\nChallenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.\nWhen thick smear positive, of at day 21 after challenge, a standard 3 day  treatment of Malarone will be given."
            }, 
            {
                "arm_group_label": "Chloroquine/Azithromycin  and falciparum immunization", 
                "arm_group_type": "Experimental", 
                "description": "This arm will receive chloroquine and azithromycin prophylaxis and three times 5 infected mosquito-bites (immunizations).\nStandard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.\nAzithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.\nChallenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.\nWhen thick smear positive, of at day 21 after challenge, a standard 3 day  treatment of Malarone will be given."
            }, 
            {
                "arm_group_label": "Chloroquine and Azithromycin control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "This arm will receive chloroquine and azithromycin prophylaxis and three times 5 uninfected mosquito-bites during immunization. Standard Chloroquine prophylactic regime: a loading dose of 300 mg on day 1 and day 3 and then 300 mg once a week, starting on day 7, for a total duration of 13 weeks.\nAzithromycin capsules 1000mg daily on three consecutive days starting on each of three immunization days.\nChallenge: Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.\nWhen thick smear positive, of at day 21 after challenge, a standard 3 day  treatment of Malarone will be given."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the superior protective immunity of the combination of chloroquine\n      and azithromycin prophylaxis under Chemoprophylaxis Sporozoites (CPS) immunization versus a\n      standard chloroquine prophylactic regimen."
        }, 
        "brief_title": "Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Malaria, Falciparum", 
            "Chloroquine", 
            "Azithromycin", 
            "Immunization"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Malaria", 
                "Malaria, Falciparum"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 18 and \u2264 35 years healthy volunteers (males or females)\n\n          2. Good health based on history and clinical examination\n\n          3. Negative pregnancy serum test\n\n          4. For females who are sexually active: use of adequate contraception (incl. condom use)\n\n          5. Signing of the informed consent form, thereby demonstrating understanding of the\n             meaning and procedures of the study\n\n          6. Agreement to inform the general practitioner and to sign a request to release medical\n             information concerning contra-indications for participation in the study\n\n          7. Willingness to undergo a Pf controlled infection through mosquito bites\n\n          8. Agreement to stay in a hotel room close to the trial centre during a part of the\n             study (Day 7 till day 15 after challenge)\n\n          9. Reachable (24/7) by mobile phone during the whole study period\n\n         10. Available to attend all study visits\n\n         11. Agreement to refrain from blood donation to Sanquin or for other purposes, during the\n             whole study period\n\n         12. Willingness to undergo HIV, hepatitis B and hepatitis C tests\n\n         13. Negative urine toxicology screening test at screening visit and the day before\n             challenge\n\n         14. Willingness to take a prophylactic regime of chloroquine or chloroquine/azithromycin\n             combination and a curative regimen of Malarone\u00ae after challenge.\n\n        Exclusion Criteria:\n\n          1. History of malaria\n\n          2. Plans to travel to malaria endemic areas during the study period\n\n          3. Plans to travel outside of the Netherlands during the challenge period\n\n          4. History of stay in malaria endemic areas for more than 6 months\n\n          5. Previous participation in any malaria vaccine study and/or positive serology for Pf\n\n          6. Symptoms, physical signs and laboratory values suggestive of systemic disorders\n             including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency,\n             psychiatric, and other conditions which could interfere with the interpretation of\n             the study results or compromise the health of the volunteer\n\n          7. History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)\n\n          8. History of arrhythmias or prolonged QT-interval\n\n          9. Positive family history in 1st and 2nd degree relatives for cardiac events < 50 years\n             old\n\n         10. An estimated, ten year risk of fatal cardiovascular disease of \u22655%, as estimated by\n             the Systematic Coronary Risk Evaluation (SCORE) system\n\n         11. Clinically significant abnormalities in electrocardiogram (ECG) at screening\n\n         12. Body Mass Index (BMI) below 18 or above 30 kg/m2\n\n         13. Any clinically significant deviation from the normal range in biochemistry or\n             haematology blood tests or in urine analysis\n\n         14. Positive HIV, HBV or HCV tests\n\n         15. Participation in any other clinical study within 30 days prior to the onset of the\n             study\n\n         16. Enrolment in any other clinical study during the study period\n\n         17. Pregnancy or lactation for women\n\n         18. Volunteers unable to give written informed consent\n\n         19. Volunteers unable to be closely followed for social, geographic or psychological\n             reasons\n\n         20. History of (soft) drugs or alcohol abuse interfering with normal social function\n\n         21. A history of treatment for psychiatric disease\n\n         22. A history of epileptic insults in the volunteer\n\n         23. Contra-indications for use of Malarone\u00ae, chloroquine or azithromycin. This includes\n             hypersensitivity or treatment taken by the volunteer that interferes with mentioned\n             study drugs.\n\n         24. The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying\n             drugs within three months of study onset (topical corticosteroids and oral\n             anti-histaminic are allowed) and during the study period\n\n         25. Any confirmed or suspected immunosuppressive or immunodeficient condition, including\n             (functional) asplenia\n\n         26. Co-workers or trainees of the departments of Medical Microbiology, Parasitology, or\n             Internal Medicine of the Leiden University Medical Centre\n\n         27. A history of sickle cell anaemia, sickle cell trait, thalassemia, thalassemia trait\n             or G6PD deficiency"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01783340", 
            "org_study_id": "MMV", 
            "secondary_id": "NL42517.000.12"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Chloroquine/Azithromycin  and falciparum immunization", 
                    "Chloroquine and Azithromycin control"
                ], 
                "intervention_name": "Azithromycin capsules", 
                "intervention_type": "Drug", 
                "other_name": "Zithromax"
            }, 
            {
                "arm_group_label": "Chloroquine and falciparum immunization", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo"
            }, 
            {
                "arm_group_label": [
                    "Chloroquine and falciparum immunization", 
                    "Chloroquine/Azithromycin  and falciparum immunization"
                ], 
                "intervention_name": "Immunization with falciparum", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": [
                    "Chloroquine and falciparum immunization", 
                    "Chloroquine/Azithromycin  and falciparum immunization", 
                    "Chloroquine and Azithromycin control"
                ], 
                "intervention_name": "Atovaquone/Proguanil", 
                "intervention_type": "Drug", 
                "other_name": "Malarone"
            }, 
            {
                "arm_group_label": [
                    "Chloroquine and falciparum immunization", 
                    "Chloroquine/Azithromycin  and falciparum immunization", 
                    "Chloroquine and Azithromycin control"
                ], 
                "intervention_name": "Challenge with falciparum", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Chloroquine", 
                "Chloroquine diphosphate", 
                "Proguanil", 
                "Atovaquone", 
                "Malarone", 
                "Azithromycin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Malaria", 
            "P falciparum", 
            "Chloroquine", 
            "Azithromycin", 
            "Immunization"
        ], 
        "lastchanged_date": "January 31, 2013", 
        "location": {
            "contact": {
                "email": "r.schats@lumc.nl", 
                "last_name": "Remko Schats, MD", 
                "phone": "0031715262620"
            }, 
            "contact_backup": {
                "email": "l.g.visser@lumc.nl", 
                "last_name": "Leo Visser, MD PhD", 
                "phone": "0031715262620"
            }, 
            "facility": {
                "address": {
                    "city": "Leiden", 
                    "country": "Netherlands", 
                    "zip": "2333ZA"
                }, 
                "name": "Leiden University Medical Centre"
            }, 
            "investigator": [
                {
                    "last_name": "Remko Schats, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Leo Visser, MD PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Maurits van Meer, MD PhD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "3", 
        "official_title": "Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis", 
        "overall_contact": {
            "email": "r.schats@lumc.nl", 
            "last_name": "Remko Schats, MD", 
            "phone": "0031715262620"
        }, 
        "overall_contact_backup": {
            "email": "l.g.visser@lumc.nl", 
            "last_name": "Leo Visser, MD, PhD", 
            "phone": "0031715262620"
        }, 
        "overall_official": [
            {
                "affiliation": "Radboud University", 
                "last_name": "RW Sauerwein, MD PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Leiden University Medical Centre", 
                "last_name": "LG Visser, MD PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Percentage of P. falciparum thick smear negative volunteers on day 21 (protection against challenge infection)", 
            "measure": "Volunteers falciparum positive by thick smear", 
            "safety_issue": "No", 
            "time_frame": "One year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01783340"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "results_reference": {
            "PMID": "19641203", 
            "citation": "Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, R\u00e9nia L, van der Ven A, Hermsen CC, Sauerwein R. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009 Jul 30;361(5):468-77."
        }, 
        "secondary_outcome": [
            {
                "description": "Duration of pre-patent period after challenge infection as measured by microscopy (thick smear)", 
                "measure": "Duration of pre-patent period by thick smear", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "Development of parasitemia as measured by PCR", 
                "measure": "Kinetics of parasitemia by PCR", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }, 
            {
                "description": "Frequency of adverse events in study groups", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "One year"
            }, 
            {
                "description": "Immune responses between study groups", 
                "measure": "Immune responses", 
                "safety_issue": "No", 
                "time_frame": "One year"
            }
        ], 
        "source": "Radboud University", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Leiden University Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Medicines for Malaria Venture", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}